Major Depressive Disorder

SPL026 with supportive therapy sees positive results in patients with major depressive disorder.

Catatonia: learn more about how to best diagnose early.

Is inflammation a biomarker of antidepressant efficacy? Researchers analyzed blood CRP levels as a predictor of response to antidepressants.

Charles Montano, MD, and Carmen Kosicek, MSN, PMHNP-BC, provide advice regarding monitoring for adverse events and compliance with different classes of MDD treatment and review suggestions for follow-up and special patient populations.

Experts in psychiatry share their thoughts on the perception of MDD within the healthcare community and the implications of this condition being viewed as chronic vs episodic.

There may not be a diagnosis for ‘New Year Depression,’ about 10% to 20% of individuals in the US may get a milder form of these winter blues.

Metabolic depression? Researchers performed a metabolomic evaluation of patients with treatment-resistant depression.

From current treatments for cannabis use disorder to new possibilities for the treatment of dementia, here are highlights from the week in Psychiatric Times.

Carmen Kosicek, MSN, PMHNP-BC, and Charles Montano, MD, comment on the interplay between depression and other comorbid psychiatric and medical health conditions as well as the economic impact of MDD.

Charles Montano, MD; Carmen Kosicek, MSN, PMHNP-BC; and Gus Alva, MD, DFAPA, review the impact of the duration of MDD episodes and goals of managing episode recurrences.

Cariprazine is now FDA-approved as an adjunctive therapy to antidepressants.

From an in-depth analysis of ADHD in clinical practice to differences in effectiveness between intravenous and intranasal ketamine, here are highlights from the week in Psychiatric Times.

This latest submission completes the FDA filing that was initiated in May.

Does route of administration affect antidepressant efficacy of ketamine? Researchers performed a meta-analysis of trials comparing intravenous and intranasal administration.

Here’s why most of the claims recently made about antidepressants in Newsweek are wrong.

The first patient in a phase 2/3 study evaluating ulotaront for MDD has been enrolled.

In this CME article, learn how to apply novel treatment approaches for patients with bipolar depression.

Postpartum depression and major depressive disorder in pregnant and postpartum women are severely underdiagnosed and undertreated. How can we more effectively help this patient population?

Is there one state-of-the-art treatment for depression?

In the case of antidepressants, a few recent articles may make it tempting to throw the baby out with the bathwater. But on close examination, that would be a mistake on many levels...

D for Depression? Researchers performed a 12-week, randomized, double-blind placebo-controlled trial of vitamin D augmentation for major depression with vitamin D deficiency.

According to new research, treating depression in older adults could decrease risk of dementia by 51%.

In this CME article, explore the mental health consequences associated with the COVID-19 pandemic as well as the potential role for complementary and alternative approaches.

“Fishing” for novel approaches to depression: Researchers performed randomized dose-finding trial of omega-3 fatty acids for depression with inflammation.

At-home ketamine treatment initiated by an online provider presents many legal, clinical, and ethical challenges...